Imaging apolipoprotein AI in vivo

Summary, in English

Coronary disease risk increases inversely with high-density lipoprotein (HDL) level. The measurement of the biodistribution and clearance of HDL in vivo, however, has posed a technical challenge. This study presents an approach to the development of a lipoprotein MRI agent by linking gadolinium methanethiosulfonate (Gd[MTS-ADO3A]) to a selective cysteine mutation in position 55 of apo AI, the major protein of HDL. The contrast agent targets both liver and kidney, the sites of HDL catabolism, whereas the standard MRI contrast agent, gadolinium-diethylenetriaminepentaacetic acid-bismethylamide (GdDTPA-BMA, gadodiamide), enhances only the kidney image. Using a modified apolipoprotein AI to create an HDL contrast agent provides a new approach to investigate HDL biodistribution, metabolism and regulation in vivo. Copyright (C) 2011 John Wiley & Sons, Ltd.

• Author: Renuka Sriram; Jens Lagerstedt; Jitka Petrlova; Haris Samardzic; Ulrike Kreutzer; Hongtao Xie; George A. Kaysen; Jean F. Desreux; David Thonon; Vincent Jacques; Martha Van Loan; John C. Rutledge; Michael N. Oda; John C. Voss; Thomas Jue
• Department/s: Cellular Biomechanics; EXODIAB: Excellence of Diabetes Research in Sweden
• Publishing year: 2011
• Language: English
• Pages: 916-924
• Publication/Series: NMR in Biomedicine
• Volume: 24
• Issue: 7
• Links: http://dx.doi.org/10.1002/nbm.1650
• Document type: Journal article
• Publisher: John Wiley & Sons Inc.
• Topic: Radiology, Nuclear Medicine and Medical Imaging
• Keywords: NMR; apolipoprotein; HDL; contrast agent; MRI; gadolinium; cardiovascular risk
• Status: Published
• Research group: Cellular Biomechanics
• ISBN/ISSN/Other: ISSN: 0952-3480